253 related articles for article (PubMed ID: 36077300)
1. Erythro-Magneto-HA-Virosome: A Bio-Inspired Drug Delivery System for Active Targeting of Drugs in the Lungs.
Vizzoca A; Lucarini G; Tognoni E; Tognarelli S; Ricotti L; Gherardini L; Pelosi G; Pellegrino M; Menciassi A; Grimaldi S; Cinti C
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077300
[TBL] [Abstract][Full Text] [Related]
2. Design of an innovative platform for the treatment of cerebral tumors by means of erythro-magneto-HA-virosomes.
Lucarini G; Sbaraglia F; Vizzoca A; Cinti C; Ricotti L; Menciassi A
Biomed Phys Eng Express; 2020 May; 6(4):045005. PubMed ID: 33444266
[TBL] [Abstract][Full Text] [Related]
3. Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer.
Grifantini R; Taranta M; Gherardini L; Naldi I; Parri M; Grandi A; Giannetti A; Tombelli S; Lucarini G; Ricotti L; Campagnoli S; De Camilli E; Pelosi G; Baldini F; Menciassi A; Viale G; Pileri P; Cinti C
J Control Release; 2018 Jun; 280():76-86. PubMed ID: 29733876
[TBL] [Abstract][Full Text] [Related]
4. Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds.
Cinti C; Taranta M; Naldi I; Grimaldi S
PLoS One; 2011 Feb; 6(2):e17132. PubMed ID: 21373641
[TBL] [Abstract][Full Text] [Related]
5. Novel epigenetic target therapy for prostate cancer: a preclinical study.
Naldi I; Taranta M; Gherardini L; Pelosi G; Viglione F; Grimaldi S; Pani L; Cinti C
PLoS One; 2014; 9(5):e98101. PubMed ID: 24851905
[TBL] [Abstract][Full Text] [Related]
6. Passive lung-targeted drug delivery systems via intravenous administration.
Wei Y; Zhao L
Pharm Dev Technol; 2014 Mar; 19(2):129-36. PubMed ID: 23336716
[TBL] [Abstract][Full Text] [Related]
7. Subcellular drug targeting, pharmacokinetics and bioavailability.
Leucuta SE
J Drug Target; 2014 Feb; 22(2):95-115. PubMed ID: 24188545
[TBL] [Abstract][Full Text] [Related]
8. Engineered nanoparticulate drug delivery systems: the next frontier for oral administration?
Diab R; Jaafar-Maalej C; Fessi H; Maincent P
AAPS J; 2012 Dec; 14(4):688-702. PubMed ID: 22767270
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary drug delivery systems: recent developments and prospects.
Courrier HM; Butz N; Vandamme TF
Crit Rev Ther Drug Carrier Syst; 2002; 19(4-5):425-98. PubMed ID: 12661699
[TBL] [Abstract][Full Text] [Related]
10. Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations.
Ngan CL; Asmawi AA
Drug Deliv Transl Res; 2018 Oct; 8(5):1527-1544. PubMed ID: 29881970
[TBL] [Abstract][Full Text] [Related]
11. Nonviral pulmonary delivery of siRNA.
Merkel OM; Kissel T
Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
[TBL] [Abstract][Full Text] [Related]
12. Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano-bio interactions.
Zhang M; Lu H; Xie L; Liu X; Cun D; Yang M
Adv Drug Deliv Rev; 2023 Dec; 203():115144. PubMed ID: 37995899
[TBL] [Abstract][Full Text] [Related]
13. Nanocarriers Made from Non-Ionic Surfactants or Natural Polymers for Pulmonary Drug Delivery.
Carter KC; Puig-Sellart M
Curr Pharm Des; 2016; 22(22):3324-31. PubMed ID: 27087597
[TBL] [Abstract][Full Text] [Related]
14. Selected Engineering and Physicochemical Aspects of Systemic Drug Delivery by Inhalation.
Sosnowski TR
Curr Pharm Des; 2016; 22(17):2453-62. PubMed ID: 26818874
[TBL] [Abstract][Full Text] [Related]
15. Development of a macrophage-targeting and phagocytosis-inducing bio-nanocapsule-based nanocarrier for drug delivery.
Li H; Tatematsu K; Somiya M; Iijima M; Kuroda S
Acta Biomater; 2018 Jun; 73():412-423. PubMed ID: 29673839
[TBL] [Abstract][Full Text] [Related]
16. Recent update of toxicity aspects of nanoparticulate systems for drug delivery.
Patnaik S; Gorain B; Padhi S; Choudhury H; Gabr GA; Md S; Kumar Mishra D; Kesharwani P
Eur J Pharm Biopharm; 2021 Apr; 161():100-119. PubMed ID: 33639254
[TBL] [Abstract][Full Text] [Related]
17. Effect of the Route of Administration and PEGylation of Poly(amidoamine) Dendrimers on Their Systemic and Lung Cellular Biodistribution.
Zhong Q; Merkel OM; Reineke JJ; da Rocha SR
Mol Pharm; 2016 Jun; 13(6):1866-78. PubMed ID: 27148629
[TBL] [Abstract][Full Text] [Related]
18. Nanocrystals based pulmonary inhalation delivery system: advance and challenge.
Yue P; Zhou W; Huang G; Lei F; Chen Y; Ma Z; Chen L; Yang M
Drug Deliv; 2022 Dec; 29(1):637-651. PubMed ID: 35188021
[TBL] [Abstract][Full Text] [Related]
19. Evaluating UiO-66 Metal-Organic Framework Nanoparticles as Acid-Sensitive Carriers for Pulmonary Drug Delivery Applications.
Jarai BM; Stillman Z; Attia L; Decker GE; Bloch ED; Fromen CA
ACS Appl Mater Interfaces; 2020 Sep; 12(35):38989-39004. PubMed ID: 32805901
[TBL] [Abstract][Full Text] [Related]
20. Targeted drug nanocrystals for pulmonary delivery: a potential strategy for lung cancer therapy.
Kumar M; Jha A; Dr M; Mishra B
Expert Opin Drug Deliv; 2020 Oct; 17(10):1459-1472. PubMed ID: 32684002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
